KRAS and neoplasm: Well-known pathogenic mutations were only detected in the tumor tissues (Table 3): p.G12D in KRAS in patients S428 and S430, and p.E545K in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in patient S170.